John Ketchum
Vermögen: 459 116 $ am 30.06.2026
Vermögen: 459 116 $ am 30.06.2026
John Ketchum is currently Chairman at Ernest Pharmaceuticals, Llc since 2022 and Independent Director at Tango Therapeutics, Inc. since 2023.
Formerly, Mr. Ketchum was Senior VP & Region Head-Emerging Growth Market at Novartis Oncology, Inc. from 2014 to 2017.
Education includes an undergraduate degree from Hamilton College (New York) and an MBA from The University of North Carolina at Chapel Hill.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 14’687 ( 0.01% ) | 459 116 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TANGO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 29.08.2023 |
Ernest Pharmaceuticals, Lcc | Vorsitzender | 01.12.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Corporate Officer/Principal | 01.03.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Hamilton College (New York)
Hamilton College (New York) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that engages in discovering and delivering precision cancer medicines | Health Technology |
Ernest Pharmaceuticals, Lcc |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen